One caveat to specifically targeting HSF1 PTMs is that some PTMs increase transcriptional activity while other PTM sites decrease activity, requiring specific PTM inhibitors to ensure a pro-cancer environment is not promoted with drug treatment (133). The gene discussed is HSF1; the disease is cancer.